Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis

NCT06975787 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT06975787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06975787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
December 22, 2025
Completion date
September 10, 2029
Enrollment
90 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis (ln)